FDASmart presents a full day seminar on 9th June 2011 - Mergers and Acquisition of Indian Biopharma, pharmaceutical Mergers and Acquisition, Global Mergers and Acquisition of Indian pharmaceutial ,  mergers and acquisitions in india,  seminar on mergers and acquisitions in india, M&A: Business Mergers and Acquisitions, Company Mergers overviews, Corporate Acquisitions ,recent mergers acquisitions, business mergers and acquisitions, company mergers, business mergers, recent mergers, mergers and acquisitions, corporate mergers, recent acquisitions FDASmart presents a full day seminar on 9th June 2011 - Mergers and Acquisition of Indian Biopharma, pharmaceutical Mergers and Acquisition, Global Mergers and Acquisition of Indian pharmaceutial ,  mergers and acquisitions in india,  seminar on mergers and acquisitions in india, M&A: Business Mergers and Acquisitions, Company Mergers overviews, Corporate Acquisitions ,recent mergers acquisitions, business mergers and acquisitions, company mergers, business mergers, recent mergers, mergers and acquisitions, corporate mergers, recent acquisitions, corporate acquisitions, acquisitions, mergers & acquisitions, business acquisition, mergers acquisitions, mergers, m&a,global mergers and acquisitions 2011,mergers and acquisitions in india 2011, Indian Mergers & Acquisition s 2011, mumbai,FDASmart.com FDASmart presents a full day seminar on 9th June 2011 - Mergers and Acquisition of Indian Biopharma, pharmaceutical Mergers and Acquisition, Global Mergers and Acquisition of Indian pharmaceutial ,  mergers and acquisitions in india,  seminar on mergers and acquisitions in india, M&A: Business Mergers and Acquisitions, Company Mergers overviews, Corporate Acquisitions ,recent mergers acquisitions, business mergers and acquisitions, company mergers, business mergers, recent mergers, mergers and acquisitions, corporate mergers, recent acquisitions, corporate acquisitions, acquisitions, mergers & acquisitions, business acquisition, mergers acquisitions, mergers, m&a,global mergers and acquisitions 2011,mergers and acquisitions in india 2011, Indian Mergers & Acquisition s 2011, mumbai,FDASmart.com FDASmart presents a full day seminar on 9th June 2011 - Mergers and Acquisition of Indian Biopharma, pharmaceutical Mergers and Acquisition, Global Mergers and Acquisition of Indian pharmaceutial ,  mergers and acquisitions in india,  seminar on mergers and acquisitions in india, M&A: Business Mergers and Acquisitions, Company Mergers overviews, Corporate Acquisitions ,recent mergers acquisitions, business mergers and acquisitions, company mergers, business mergers, recent mergers, mergers and acquisitions, corporate mergers, recent acquisitions, corporate acquisitions, acquisitions, mergers & acquisitions, business acquisition, mergers acquisitions, mergers, m&a,global mergers and acquisitions 2011,mergers and acquisitions in india 2011, Indian Mergers & Acquisition s 2011, mumbai,FDASmart.com FDASmart presents a full day seminar on 9th June 2011 - Mergers and Acquisition of Indian Biopharma, pharmaceutical Mergers and Acquisition, Global Mergers and Acquisition of Indian pharmaceutial ,  mergers and acquisitions in india,  seminar on mergers and acquisitions in india, M&A: Business Mergers and Acquisitions, Company Mergers overviews, Corporate Acquisitions ,recent mergers acquisitions, business mergers and acquisitions, company mergers, business mergers, recent mergers, mergers and acquisitions, corporate mergers, recent acquisitions, corporate acquisitions, acquisitions, mergers & acquisitions, business acquisition, mergers acquisitions, mergers, m&a,global mergers and acquisitions 2011,mergers and acquisitions in india 2011, Indian Mergers & Acquisition s 2011, mumbai,FDASmart.com FDASmart presents a full day seminar on 9th June 2011 - Mergers and Acquisition of Indian Biopharma, pharmaceutical Mergers and Acquisition, Global Mergers and Acquisition of Indian pharmaceutial ,  mergers and acquisitions in india,  seminar on mergers and acquisitions in india, M&A: Business Mergers and Acquisitions, Company Mergers overviews, Corporate Acquisitions ,recent mergers acquisitions, business mergers and acquisitions, company mergers, business mergers, recent mergers, mergers and acquisitions, corporate mergers, recent acquisitions, corporate acquisitions, acquisitions, mergers & acquisitions, business acquisition, mergers acquisitions, mergers, m&a,global mergers and acquisitions 2011,mergers and acquisitions in india 2011, Indian Mergers & Acquisition s 2011, mumbai,FDASmart.com FDASmart presents a full day seminar on 9th June 2011 - Mergers and Acquisition of Indian Biopharma, pharmaceutical Mergers and Acquisition, Global Mergers and Acquisition of Indian pharmaceutial ,  mergers and acquisitions in india,  seminar on mergers and acquisitions in india, M&A: Business Mergers and Acquisitions, Company Mergers overviews, Corporate Acquisitions ,recent mergers acquisitions, business mergers and acquisitions, company mergers, business mergers, recent mergers, mergers and acquisitions, corporate mergers, recent acquisitions, corporate acquisitions, acquisitions, mergers & acquisitions, business acquisition, mergers acquisitions, mergers, m&a,global mergers and acquisitions 2011,mergers and acquisitions in india 2011, Indian Mergers & Acquisition s 2011, mumbai,FDASmart.com FDASmart presents a full day seminar on 9th June 2011 - Mergers and Acquisition of Indian Biopharma, pharmaceutical Mergers and Acquisition, Global Mergers and Acquisition of Indian pharmaceutial ,  mergers and acquisitions in india,  seminar on mergers and acquisitions in india, M&A: Business Mergers and Acquisitions, Company Mergers overviews, Corporate Acquisitions ,recent mergers acquisitions, business mergers and acquisitions, company mergers, business mergers, recent mergers, mergers and acquisitions, corporate mergers, recent acquisitions, corporate acquisitions, acquisitions, mergers & acquisitions, business acquisition, mergers acquisitions, mergers, m&a,global mergers and acquisitions 2011,mergers and acquisitions in india 2011, Indian Mergers & Acquisition s 2011, mumbai,FDASmart.com 

“Global Mergers & Acquisitions of Indian BioPharma:
Boom or Bust for the Indian Pharmaceutical Industry?”


 
A Full One-Day Forum with Networking on Key Issues & Topics that Will
Affect & Change the Indian Pharmaceutical Industry ( for Better or for Worse ) !
 
.
Venue : ITC The Grand Central Hotel, Mumbai, India. .
Address: Dr. Babasaheb Ambedkar Road, Parel - Mumbai 
Date : June 9th, 2011 - 8:30-5:30pm
   
Knowledge
Partner:
Sole Banking
Partner:
 
June 9th – Full Day Agenda:

08:30 a.m - 09:35 a.m : Registration – Networking
 
09:35 a.m - 9:40 a.m : Opening Remarks / Welcome
Mr. Ram Balani CEO-Founder- FDASmart Inc. (Event Organizer)    
 
Session 1: “Quovadis Pharma Industry – CEO’s Ringside View”
 
9:40 a.m -10:20 a.m : Mr. Ranjit Shahani – Vice Chairman/Managing Director - Novartis India Ltd.
 
Description: Ranjit Shahani will take us a thru a quick pharmaceutical tour back in time, then roll the clocks forward highlighting key trends that will shape the future, discussing major challenges as these changes unfold with special focus in emerging pharmaceutical markets from a major pharma MNC prospective.

Mr. Shahani will then probe strategic priorities and questions then shift gears towards pharmaceutical mergers & acquisitions
 
Speaker Background :
. Mr. Ranjit Shahani is Country President Novartis India responsible for the overall operations of the Novartis AG Companies in India

He started his career with ICI in India in their businesses of Fibres & Speciality chemicals. Later, he rose to the position of General Manager with ICI / ZENECA in the U.K., overseeing their Asia Pacific and LatAm operations for their Petrochemicals and Plastics division.

This was followed by a period as CEO at Roche Products Limited, after which he moved to Novartis in India in 1997, following the merger of Sandoz and Ciba-Geigy.

Mr Shahani is President, Organisation of Pharmaceuticals Producers of India (OPPI), an organization he also lead earlier from 2001-2007, is Past President of the Bombay Chamber of Commerce and Industry, President, Swiss Indian Chamber of Commerce, and was on the Council of the International Federation of Pharmaceuticals Manufacturers Associations (IFPMA, Geneva). He is a thought leader in the Pharmaceutical Industry and has been actively involved in lobbying for a strong Product Patent law in the country and Data Protection and liberalization of the price control mechanism for Pharmaceuticals. He has also strongly canvassed for deterrent legislation against counterfeit drugs.

A Mechanical Engineer from IIT Kanpur and MBA from JBIMS, Bombay, was born in Kanpur, India, is married and his wife is a well known educationist and currently also the Sheriff of Mumbai - they have one son - who works with McKinsey in London.  
 
 
Session 2: “Why FDI (Foreign Direct Investment) in Indian Pharma Need Not be Curbed” 
 
10:20 a.m -10:50 a.m : Dr. Sumit Ghoshal – Deputy Editor - Business India - Mumbai.
 
Description : Mergers and acquisitions involving Indian companies have caused lot of concern in the Indian government and the industry. However, the fact is, a variety of deals are being worked out, including some joint ventures. An FDI cap could hurt them all, and restrict the growth of Indian companies. The way to protect Indian industry is to make them stronger, and not help them hide behind the apron strings of the government.
 
Speaker Background :
...

Dr. Sumit Ghoshal serves as Deputy Editor in Business India.

Sumit Ghoshal is a healthcare writer with 24 years of full time experience in mainstream newspapers and magazines in Mumbai, mostly with the Indian Express. From May 2006 till the present time,  Dr. Ghoshal has been working in a senior position with Business India magazine, writing extensively on pharmaceuticals, healthcare delivery, biotechnology and life sciences.
 Dr. Ghoshal began his journalism career  with  newspapers in September 1986 about four years after completing his  medical degree from Gandhi Medical College in Bhopal. The four years  he  spent  working as a resident doctor in leading hospitals in Mumbai provided a rich backdrop for his  work in  healthcare journalism later on.

Earlier, from July 2002 to April 2004, he served  as an Associate Editor with Pharmabiz Hospital Review, a fortnightly paper for the Indian healthcare industry. At one point, in 1995-96, he  was the most prolific writer in India on nuclear energy and in March 1996, and he broke the biggest story in India about dangers of nuclear power.

Additionally,  his  first novel titled In the Pink of Wealth was launched on in April 2004.
 He has   also written articles for the LANCET, Canadian Medical Association Journal and the Medical Post of Toronto.

Over the years, Dr. Ghoshal   has been constantly associated with social organizations such as Breast Feeding Promotion Network of India, Family Planning Association of India and UNICEF apart from Indian Academy of Pediatrics and Indian Medical Association.
 
Session 3: "What Next for the Global Pharma Supply Chain?" 
 

10:50 a.m –11:20 a.m :

Mr. Chris Barnett - Principal - CMBarnett Pharma Services Ltd.
 
Description : What happens when the merger or acquisition “honeymoon is over” between two pharmaceutical companies?

Mr. Chris Barnett will cover a history leading up to today’s global pharma supply chain followed by a a quick review of the current situation highlighting differences between East /West and future prediction where things could go.

Quality when not “nursed” and harmonized after two pharmaceutical companies are merged or one is acquired by another could have catastrophic results indeed. We need not go too far back to cite what happened with Ranbaxy GMP debacles soon after Daiichi Sankyo acquired India’s poster pharmaceutical company, i.e. to say a melt-down occurred is to put it mildly.

Chris in his capacity as a UK based QP (Qualified Person) will cite examples of mergers or acquisitions “gone wild” from ignoring GMP compliance and ignoring company cultures with their inherent biased towards supply chain quality.

During his presentation, Chris will paint a picture where EU and US become the low-cost manufacturers dancing to the tune of the innovators in India, China to support the growing markets in Latin America, i.e. a pharmaceutical world turned up-side down so to speak, i.e. Chris Barnett will explore and propose how it could happen !
 
Speaker Background :
Chris Mr. Chris had over 30 years international experience with major pharmaceutical companies covering analytical chemistry, QA management, technology transfer, GMP and manufacturing strategy. Based in the UK, Chris has worked in both India and Mexico and speaks fluent Spanish. Following a successful 20-year career with what was to become GlaxoSmithKline, from 2002 to 2008 he was a managing partner in a UK-based pharmaceutical consultancy practice. He currently works as independent GMP consultant and advisor to small and medium-sized pharmaceutical companies. He specialises in GMP and quality systems, auditing, validation, and contractor management. He is also a member of the Scientific Advisory Board for Greenwich University in the UK.

Eligible for nomination as a Qualified Person on European manufacturing licences, he is a Fellow of the Royal Society of Chemistry, a member of ISPE and of the Pharmaceutical Quality Group, and has trained as an ISO9000 lead auditor  
 
11:20 a.m -11:30 a.m : Nishith Desai & Associates - Sponsor Welcome
 
11:30 a.m -12:00 p.m : Tea / Coffee Break / Networking
 
Speaker 4 : “Navigating the Legal Maze in Doing Business with Pharma Company in India…. Legal and Investment Perspective”
 
12:00 p.m - 12:45 p.m : Dr. Milind Antani- Head- Pharmaceutical & Life Sciences - Nishith Desai & Associates.
 
Description : The pharma sector has seen at least six big-ticket takeovers in the past five years. Among them was the 2008 acquisition of the country's largest drug maker, Ranbaxy, by Japanese firm Daiichi Sankyo for $ 4.6 billion. Piramal Health Care's domestic business was recently acquired by US-based Abbot Laboratories for $3.7 billion and possibly many more are in pipeline.

With Indian generics accounting for 72% of the total US pharma market volume in 2009 – an all-time high in the world’s biggest pharma market-there is bound to be evenmore interest in M&As with Indian pharma in the days to come. Recently we have witnessed significant inbound deals in pharma sector in India.

There is great concern whether justified or not with Indian pharma being for outright sale! The government has asked constitution of an inter-ministerial group to review India’s foreign direct investment norms in the pharmaceutical sector in India. Add to that the confusion arising around this issue: “The government has suggested that foreign direct investment (FDI) in greenfield pharmaceutical projects will continue unhindered, but companies that receive government funds for research could face some restrictions.”

Whatever happens, FDI curb or not, the dynamics and legal ramifications of today’s pharmaceutical M&A will greatly impact the Indian pharma sector. Dr. Antani during his presentation will provide an overview of today’s M&A from a legal and FDI perspective.
 
Speaker Background :
. Dr. Antani heads the Pharma and Life Sciences Practice at the multi-skilled, research-based international law firm, Nishith Desai Associates with offices in Mumbai, Silicon Valley, Bangalore and Singapore.

Dr. Antani represents clients in matters including corporate mergers and acquisitions, regulatory and transactional matters, intellectual property prosecution and litigation, joint ventures and formation of new companies.
 
 
. Simone Reis - Senior Member M & A Team - Based in Mumbai, Simone is a core member of the Mergers and Acquisitions and the Fund Investment practice at the firm. Simone’s practice focuses on mergers and acquisitions, competition law issues, private equity and venture capital investments, domestic and international, and has advised a wide spectrum of clients, including companies and financial advisors, across several sectors such as pharma and healthcare, manufacturing, information technology, banking and financial services and real estate.

Simone completed her LLM from Duke University, North Carolina, USA in 2009 where her area of study included mergers and acquisitions and corporate finance. Simone is also licensed to practice in the state of New York, USA and is enrolled in the New York state bar. Simone has been a member of the Bar Council of Maharashtra and Goa since 2005.
 
Session 5: “ Pharmaceutical Mergers, Acquisitions and Firm’s Performance: Under the Hood Realities”
 
12:45 p.m - 1:15 p.m : Dr. Pulak Mishra -Assistant Professor, Department of Humanities and Social Sciences, Indian Institute of Technology Kharagpur, Kharagpur. 
 
Description : In the context of policy reforms in the 1990s in general and three important amendments made to the Indian Patent Act (1970) in 1999, 2002 and 2005 in particular, the Dr. Mishra will make an attempt to examine the impact of MA on financial performance of Indian pharmaceutical companies.

It is found that theprofitability of a firm depends directly on its size, selling efforts and exports andimports intensities but inversely on their market share and demand for the products.

However, MA do not have any significant impact on profitability of the firms in the long run possibly due to the resultant X-inefficiency and entry of new firms into the market.

In addition, in-house R&D and foreign technology purchase also do not have any significant impact on profitability of the firms.

There are two broad theories explaining why firms acquire other firms or merge with other firm. The monopoly theory postulates that the firms use the M&A route to raise their market power , whereas, according to the efficiency theory, M&As are planned and executed to reduce costs by achieving scale economies.

Either way firms are expected to have better financial performance following M&As. But what really happens in the real world? His revelations may just surprise most of us ! His conclusions: “ Indian pharmaceutical firms fail to reap the benefits of MA in terms of Profitability but M&As in Indian pharmaceutical industry are not necessarily counterproductive and detrimental to the interests of the consumers.
 
Speaker Background :
. Dr. Mishra has more than 16 years of teaching and research experience. His current research interests include technology strategies of Indian firms, mergers and acquisitions, competition policy and issues related to rural development.

He recently published a paper on “Mergers, Acquisitions and Firms’ Performance:

Experience of Indian Pharmaceutical Industry” with the Eurasian Journal of Business and Economics 2010.

He is also involved in a number of research projects sponsored by MORD, NFCG, and MOE&F. He has published a number of research papers in reputed national and international journals.
 
 
1:15 p.m -2:30 p.m : Lunch Break / Networking
 
Session 6: "Spate in M&A Activity in Indian Pharmaceuticals – Boon or Bane" 
 
2:30 p.m - 3:00 p.m : Mr. Anjan Sen - Director, Strategy & Operations - Deloitte India.
 
Description : The recent spate of Mergers and Acquisitions (M & A) is rewriting the course of the Indian pharmaceuticals industry. Whether the impact of this M&A flurry on the close to US $ 10 billion pharmaceuticals market is constructive or disparaging – only time will tell. The motivation driving such activity can be better understood if one looks into the rationality aspects, and which will further characterize the future of the pharmaceuticals industry.

Potential rationale and triggers abound. With research pipelines running dry, patents of many blockbusters nearing expiry, stagnating growths in large developed markets and increasing pricing pressures, MNCs are transforming their business mantra to survive and looking at driving growths from the emerging markets. In addition, with improvement in life expectancy resulting in increase of chronic and lifestyle diseases, most Governments in developed nations are battling ballooning healthcare expenditure and increasingly looking at generics to contain healthcare costs. Indian companies with their USFDA / EMEA approved generic programs, low cost manufacturing facilities, matured value chains, and well trained field force are becoming potential targets.

What does it lead to? Growth, consolidation, increased competitive viability, prudent leverage of complementarities of core competencies (R&D, manufacturing, marketing, etc.) and financial stability leading towards market leadership. However, industry experts and government are wary about potential negative trends such as dampening product and process innovation, inculcation of short term value achievement, diversion of resources from innovations to other activities such as contract manufacturing, curbing of global aspirations, increase in prices of medicines and looking for exit strategies.

In our discussion, we plan on covering and analyzing the rationale behind such M&A and licensing activities and a framework to analyze the key motivations. In addition, we plan on providing our perspective of the future evaluating both, the perceived positive and negative effects.
 
Speaker Background :
. Mr. Anjan Sen is Director, Strategy & Operations at Deloitte India. He has over 20 years of experience in different capacities in the pharmaceuticals industry in India, Middle East, Africa, Israel and Turkey. He has extensive experience in devising corporate growth strategies, building successful alliances, due diligence and M&A having led and managed post merger integration for three large mergers.

Anjan specializes in market and growth strategies and has been responsible for building large brands, managing strategic portfolios, driving growth and profitability. improvement strategies and improving operational efficiencies. His clients include Johnson & Johnson, Pfizer, Roche Diagnostics, National Institute of Pharmaceutical Education and Research (NIPER) and Boehringer Ingelheim.

Anjan’s experience includes managing large transformation projects in different capacities and organizations providing Project Guidance and Management expertise in the areas of corporate and growth strategy, customer, channel & market strategy, mergers and acquisitions in Life Sciences & Health Care industry.

Anjan was a member of the Marketing Committee of Organization of Pharmaceutical Producers of India (OPPI) and is a current member of the Pharmaceutical Committee of American Chamber of Commerce. He has undergone a leadership Development Program with the Harvard Business School, USA. Anjan has a masters in Business Management from Indian Institute of Management, Lucknow and graduated from Indian Institute of Technology, Kharagpur 
 
 
Session 7: "M&As in the Indian CRO Sector: What's Next?"
 
3:00 p.m - 3:30 p.m : Dr Kiran Marthak - Director - Veeda Clinical Research
 
Description : Dr. Kiran Marthak will briefly present major mergers & acqusitions of Indian pharmaceutical companies made by foreign corporate entities. He will then discuss high profile M&As with CRO companies themselves and summarize net results to the CRO industry as these M&As progress in time. Dr. Marthak will highlight the Veeda CRO story and their acquisition strategies & track record in the last few years including companies in Belgium, UK and the USA. Dr. Marthak will discuss, among other things, the Veeda CR enhanced service profiles, their strategy & growth curve. He will also compare the impact on the CRO industry when a foreign company acquires an Indian CRO versus the opposite case where an Indian CR does the acquisition.
 
Speaker Background :
a Dr. Marthak is a member of Veeda Clinical Research’s Board of Directors and has more than 25 years of active participation in the field of clinical research and a number of scientific qualifications and publications to his credit. Dr Marthak has an M D medicine awarded from Dr. Grant Medical College and is also a Business Management Degree holder.

Dr Marthak has vast experience in Phase I clinical research working for Novartis for 13 years pioneering phase I studies in India as early as 1978-79. Dr Marthak has also initiated clinical trials for USFDA submission and data management while working with Pfizer as Vice President Clinical Research. More recently Dr Marthak has worked with Ranbaxy as Vice President Clinical Research and with German Remedies as Medical Director

Dr Marthak is actively involved with regulatory authorities like US FDA, UK MHRA, China SFDA, South Africa MCC, MHCW and India –DCGI He is a Member of the Medical Committee- Indian Drug Manufacturer’s Association, a Member-India Task Force- DIA, USA, a Founder Member- Clinical Research Institute, India and a Member of the Delegation- Gujarat Government, Vibrant Gujarat.
 
Session 8: Key Trends in Financing India Life Sciences companies
 
3:30 p.m - 4:00 p.m : Mr. Vishal Gandhi - Vice President & Head , Life Sciences Banking - YES BANK
 
Description : The Indian Life Sciences sector is seeing a revival in the financing environment, post the economic crisis of 2008. However, there is a very distinct shift in the scenario now, with investors being more demanding and exact in their requirements.

Also the view points of the retail investor, PE/VC and Angel investor funds, and banks and financing institutions are increasingly diverging. This is resulting in a whole new set of opportunities and challenges, from those existing a few years before.

In his talk, Mr. Vishal Gandhi will give an insight into the investor’s point of view and will cover the various kinds of financing options available for upcoming and medium-sized Life Science companies in India at present, the associated pros and cons from a company’s perspective and the near-term outlook for these opportunities. He will also try to give a picture of the kind of funding being received by the different types of companies in the recent past, and what was the key factor that led to them receiving this, through relevant case studies.

Mr. Gandhi will also briefly touch upon the financing available to support M&A in the industry and the flow of joint-venture deals which are currently taking place along with their funding implications.
 
Speaker Background :
. Mr. Vishal Gandhi is Vice President & Head –Life Sciences Banking at YES BANK. He leads the Life Sciences Knowledge Banking initiative for YES BANK working as the key Relationship stakeholder responsible for Origination, Advisory & Execution Oversight of Corporate Banking / Investment Banking deals in the sector. He has over the past 4.5 years at YES BANK significantly developed the Life Sciences Knowledge Vertical and has been instrumental in developing a strong external equity and new client break -troughs for the Bank.

Prior to joining YES BANK in Sept/06, he has worked with FICCI, Genomic Solutions, U.K, Ranbaxy Laboratories, Dabur India Limited in various capacities, over a span of ten years. In his previous role at FICCI, Vishal was actively involved in taking up Policy issues with the various government departments to create a better business environment for Biotechnology, Healthcare & Pharmaceuticals sector. He has been a part of various business delegations to USA, China and U.K for facilitating Biotechnology and Pharma Bilateral trade.

At Ranbaxy/Dabur, he was part of business development and strategy team and implemented several initiatives successfully.

Vishal is a member of various sectoral taskforces of the respective industry associations, including CII, FICCI, ABLE, Department of Biotechnology, USIBC taskforce for Biotechnology and Nanotechnology, among others. He holds an executive management degree from XLRI, Jamshedpur with specialization in finance and strategy. He completed his master’s in Biotechnology from Central University, Hyderabad and a bachelor’s degree in Botany honours from Delhi University respectively.
 
4:00 p.m - 4:30 p.m : Tea / Coffee Break / Networking
 
Last Session
Panel Discussion :
(Audience Participation Invited at moderator discretion) 
 

4:30 p.m –5:30 p.m

Panel Moderator : Mr.Tehmasp Rustomjee - Senior Director, Financial Advisory - Deloitte India.   
 
Moderator Background :
. Mr. Tehmasp Rustomjee is one of the most experienced senior director in the Financial Advisory function. He is also heading the Life Sciences Healthcare vertical for Financial Advisory.

During Tehmasp’s professional experience of more than twenty years with the firm, he has developed expertise in a wide variety of industries and transactions and has a reputed name in valuations. He was the project leader in charge of the first successful strategic partner disinvestments/privatization in India (the firm were advisors to the Government of Gujarat for inducting a strategic partner for Gujarat Tractors Corporation Limited). He has worked with all the leading groups in India like Tata, Reliance, ITC, Murgappa, Larsen & Tourbo and multinational groups like Philips, Pfizer, Asea Brown Boveri Ltd., Hindustan Unilever Ltd, Motor Industries Company Ltd., Robert Bosch GmbH, Germany, Cummins, Novartis, Mitsui in diverse assignments including valuations, advisory services for mergers and acquisition, etc. He was the project leader for developing strategy and joint venture partner search for hospitality, healthcare, leisure and commercial vertical for the first post-independence hill station being developed by Lavasa Corporation.

Prior to joining the firm, he was with a management consulting firm for two years providing consulting services to small and medium enterprises. Prior to that, he was with Voltas Ltd for four and a half years of which in the last two years, he was in the corporate planning and diversification department.

Tehmasp has a B. Tech. Agricultural Engineering from Indian Institute of Technology, Kharagpur as well as a PGDMA, Agriculture from Indian Institute of Management, Ahmedabad.  
 
Panel Discussion Description:
  • What is the future of Indian pharmaceutical companies?
  • Does India need more acquisitions in Pharma?
  • Next wave of M&A in Pharmaceuticals
 
Panel Members:  
 
.

1- Mr. Ranjit Shahani – Vice Chairman/managing Director - Novartis India Ltd.

 
.

2- Mr. Anjan Sen - Director, Strategy & Operations - Deloitte India.

 
.

3- Dr. Milind Antani- Head- Pharmaceutical & Life Sciences - Nishith Desai & Associates.

 
4- Mr. Vishal Gandhi - Vice President & Head , Life Sciences Banking - YES BANK
.

5- Dr. Sumit Ghoshal – Deputy Editor - Business India - Mumbai.

 
.

6- Mr. Chris Barnett - Principal - CMBarnett Pharma Services Ltd.

 
.

7- Dr. Pulak Mishra -Assistant Professor, Department of Humanities and Social Sciences, Indian Institute of Technology Kharagpur, Kharagpur. 

 

5:30 p.m

Conference Ends
 
Deloitte refers to Deloitte Touche Tohmatsu India Private Limited.
 

For more information contact Sheela Bathija at 91 98207 51727 or email at rbalani@fdasmart.com
 
fdasmart.com@ 2011